Brokerages Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $14.00

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have earned a consensus recommendation of “Reduce” from the nine analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and eight have given a hold recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $14.00.

VTYX has been the topic of a number of research reports. Oppenheimer lowered shares of Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 8th. Piper Sandler cut Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 price objective on the stock. in a research note on Thursday, January 8th. Canaccord Genuity Group lowered Ventyx Biosciences from a “buy” rating to a “hold” rating and decreased their target price for the company from $16.00 to $14.00 in a research report on Thursday, January 8th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $14.00 target price on shares of Ventyx Biosciences in a report on Thursday, January 8th. Finally, Lifesci Capital restated a “market perform” rating and set a $14.00 price target on shares of Ventyx Biosciences in a research note on Thursday, January 8th.

Insider Transactions at Ventyx Biosciences

In other news, CEO Raju Mohan sold 47,345 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $365,503.40. Following the completion of the sale, the chief executive officer owned 2,372,863 shares of the company’s stock, valued at approximately $18,318,502.36. This represents a 1.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John Nuss sold 12,675 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $97,851.00. Following the transaction, the insider owned 489,481 shares in the company, valued at approximately $3,778,793.32. This represents a 2.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 14.49% of the company’s stock.

Hedge Funds Weigh In On Ventyx Biosciences

A number of large investors have recently bought and sold shares of VTYX. CWM LLC lifted its position in Ventyx Biosciences by 7.6% during the 2nd quarter. CWM LLC now owns 57,145 shares of the company’s stock worth $122,000 after acquiring an additional 4,057 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in shares of Ventyx Biosciences by 21.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 29,657 shares of the company’s stock worth $62,000 after purchasing an additional 5,174 shares during the last quarter. Prelude Capital Management LLC raised its stake in shares of Ventyx Biosciences by 35.0% in the third quarter. Prelude Capital Management LLC now owns 21,200 shares of the company’s stock worth $66,000 after purchasing an additional 5,500 shares during the last quarter. Hudson Bay Capital Management LP acquired a new stake in shares of Ventyx Biosciences during the second quarter worth about $34,000. Finally, Persistent Asset Partners Ltd purchased a new stake in Ventyx Biosciences in the third quarter valued at approximately $51,000. Institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Trading Up 0.8%

Shares of VTYX opened at $14.03 on Wednesday. The firm has a market capitalization of $1.00 billion, a P/E ratio of -9.35 and a beta of 1.23. Ventyx Biosciences has a 12-month low of $0.78 and a 12-month high of $25.00. The firm has a fifty day moving average price of $10.24 and a 200-day moving average price of $6.09.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.13. Analysts predict that Ventyx Biosciences will post -2.09 earnings per share for the current year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.